Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children : A Randomized, Double-Blind, Parallel, Placebo-Controlled Study
© 2024. The Author(s)..
INTRODUCTION: Supplementation with dietary neuro-pigments lutein (L) and zeaxanthin (Z) has been shown to improve many aspects of visual and cognitive function in adults. In this study, we tested whether a similar intervention could improve such outcomes in preadolescent children.
METHODS: Sixty children (age range 5-12 years) were randomized in a 2:1 ratio in this double-blind, placebo-controlled clinical trial. Subjects were supplemented with gummies containing either a combination of 10 mg lutein and 2 mg zeaxanthin (LZ) or placebo for 180 days. Macular pigment optical density (MPOD) was the primary endpoint. The secondary endpoints included serum levels of L and Z, and brain-derived neurotrophic factor (BDNF), critical flicker fusion (CFF), eye strain and fatigue using visual analogue scales (VAS), Children's Sleep Habits Questionnaire-Abbreviated (CSHQ-A), and Creyos Health cognitive domains like attention, focus/concentration, episodic memory and learning, visuospatial working memory, and visuospatial processing speed. Safety was assessed throughout the study on the basis of physical examination, vital signs, clinical laboratory tests, and monitoring of adverse events.
RESULTS: The LZ group showed significant increases in MPOD at all visits post-supplementation, with significant increases as early as day 42 compared to placebo. The LZ group showed significant increases in serum lutein levels, reduced eye strain and fatigue, and improved cognitive performance (focus, episodic memory and learning, visuospatial working memory) at days 90 and 180 compared to placebo. Further, the LZ group showed significant increases in processing speed (CFF), attention, visuospatial processing, and serum Z and BDNF levels on day 180 compared to placebo. No safety concerns were observed.
CONCLUSIONS: Supplementing LZ resulted in increased MPOD levels, along with increased serum levels of L, Z, and BDNF. These changes were associated with improved visual and cognitive performances and reduction in eye strain and eye fatigue in the children receiving LZ gummies. The investigational product was safe and well tolerated.
TRIAL REGISTRATION: http://ctri.nic.in/ Identifier CTRI/2022/05/042364.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 16. März, Seite 1496-1511 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Parekh, Rajesh [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s12325-024-02785-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368535339 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368535339 | ||
003 | DE-627 | ||
005 | 20240326235434.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240216s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-024-02785-1 |2 doi | |
028 | 5 | 2 | |a pubmed24n1348.xml |
035 | |a (DE-627)NLM368535339 | ||
035 | |a (NLM)38363462 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Parekh, Rajesh |e verfasserin |4 aut | |
245 | 1 | 0 | |a Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children |b A Randomized, Double-Blind, Parallel, Placebo-Controlled Study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 26.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s). | ||
520 | |a INTRODUCTION: Supplementation with dietary neuro-pigments lutein (L) and zeaxanthin (Z) has been shown to improve many aspects of visual and cognitive function in adults. In this study, we tested whether a similar intervention could improve such outcomes in preadolescent children | ||
520 | |a METHODS: Sixty children (age range 5-12 years) were randomized in a 2:1 ratio in this double-blind, placebo-controlled clinical trial. Subjects were supplemented with gummies containing either a combination of 10 mg lutein and 2 mg zeaxanthin (LZ) or placebo for 180 days. Macular pigment optical density (MPOD) was the primary endpoint. The secondary endpoints included serum levels of L and Z, and brain-derived neurotrophic factor (BDNF), critical flicker fusion (CFF), eye strain and fatigue using visual analogue scales (VAS), Children's Sleep Habits Questionnaire-Abbreviated (CSHQ-A), and Creyos Health cognitive domains like attention, focus/concentration, episodic memory and learning, visuospatial working memory, and visuospatial processing speed. Safety was assessed throughout the study on the basis of physical examination, vital signs, clinical laboratory tests, and monitoring of adverse events | ||
520 | |a RESULTS: The LZ group showed significant increases in MPOD at all visits post-supplementation, with significant increases as early as day 42 compared to placebo. The LZ group showed significant increases in serum lutein levels, reduced eye strain and fatigue, and improved cognitive performance (focus, episodic memory and learning, visuospatial working memory) at days 90 and 180 compared to placebo. Further, the LZ group showed significant increases in processing speed (CFF), attention, visuospatial processing, and serum Z and BDNF levels on day 180 compared to placebo. No safety concerns were observed | ||
520 | |a CONCLUSIONS: Supplementing LZ resulted in increased MPOD levels, along with increased serum levels of L, Z, and BDNF. These changes were associated with improved visual and cognitive performances and reduction in eye strain and eye fatigue in the children receiving LZ gummies. The investigational product was safe and well tolerated | ||
520 | |a TRIAL REGISTRATION: http://ctri.nic.in/ Identifier CTRI/2022/05/042364 | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a BDNF | |
650 | 4 | |a Blue light | |
650 | 4 | |a Cognitive performance | |
650 | 4 | |a Lutein and zeaxanthin | |
650 | 4 | |a Screen time | |
650 | 4 | |a Vision performance | |
650 | 7 | |a Lutein |2 NLM | |
650 | 7 | |a X72A60C9MT |2 NLM | |
650 | 7 | |a Zeaxanthins |2 NLM | |
650 | 7 | |a Brain-Derived Neurotrophic Factor |2 NLM | |
650 | 7 | |a Macular Pigment |2 NLM | |
700 | 1 | |a Hammond, Billy R |c Jr |e verfasserin |4 aut | |
700 | 1 | |a Chandradhara, Divya |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 4 vom: 16. März, Seite 1496-1511 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:16 |g month:03 |g pages:1496-1511 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02785-1 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2024 |e 4 |b 16 |c 03 |h 1496-1511 |